Vážanová Diana, Ďuriček Martin, Uhrík Peter, Bánovčin Peter
Clinic of Internal Medicine-Gastroenterology, University Hospital in Martin, Jessenius Faculty of Medicine, Martin, Slovakia.
Clin J Gastroenterol. 2025 Feb;18(1):43-47. doi: 10.1007/s12328-024-02066-y. Epub 2024 Dec 3.
The use of botulinum toxin in the therapy of esophageal motility disorders is reserved for elderly and comorbid patients considered risky for endoscopic or surgical treatment. However, there is a lack of data on the treatment of motility disorders outside the Chicago classification.We present the case of a 56-year-old patient with dysphagia and non-cardial chest pain (Eckardt 8). High resolution manometry ruled out achalasia or other motility disorder, but confirmed a localized 7-cm-long spastic segment in the upper to middle third of esophagus. We considered endoscopic or surgical therapy in this location too risky, therefore we decided to apply botulinum toxin into this segment. The spasm on high resolution manometry correlated with the thickened muscularis propria layer according to the endoscopic ultrasound. We used endoscopic ultrasound for the navigation of botulinum toxin application into the muscularis propria layer. We applied 100 IU of botulinum toxin into four quadrants, 20 and 24 cm from front teeth (12.5 IU for 1 application).The therapy led to improvement of symptoms (Eckardt 3) and to restitution of propulsive peristalsis with complete elimination of spastic segment. The worsening of symptoms appeared after 2 years, with subsequent recurrence of motility disorder fulfilling criteria of type II achalasia.Presenting this case, we wanted to point at the unique use of botulinum toxin as useful treatment in selected cases of unclassified esophageal motility disorder as a bridge therapy. Moreover, endoscopic ultrasound could be used to guide precise application of botulinum toxin.
肉毒杆菌毒素用于治疗食管动力障碍仅限于那些被认为进行内镜或手术治疗存在风险的老年及合并其他疾病的患者。然而,关于芝加哥分类以外的动力障碍治疗的数据却很缺乏。我们报告一例56岁有吞咽困难和非心源性胸痛(埃卡德评分8分)的患者。高分辨率测压排除了贲门失弛缓症或其他动力障碍,但证实食管上三分之一至中三分之一处有一段7厘米长的局限性痉挛段。我们认为在此部位进行内镜或手术治疗风险太大,因此决定在此段应用肉毒杆菌毒素。根据内镜超声检查,高分辨率测压显示的痉挛与固有肌层增厚相关。我们使用内镜超声引导将肉毒杆菌毒素注入固有肌层。我们在距门牙20厘米和24厘米处的四个象限各注入100国际单位肉毒杆菌毒素(每次注入12.5国际单位)。治疗后症状改善(埃卡德评分3分),推进性蠕动恢复,痉挛段完全消失。2年后症状恶化,随后动力障碍复发,符合Ⅱ型贲门失弛缓症标准。通过展示这个病例,我们想指出肉毒杆菌毒素在未分类的食管动力障碍的特定病例中作为一种过渡治疗的独特用途。此外,内镜超声可用于指导肉毒杆菌毒素的精确注射。